

RECEIVED
CENTRAL FAX CENTER
APR 27 2006

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

April 27, 2006

FACSIMILE TRANSMISSION SHEET

TO MS Amendment
COMPANY Commissioner for
Patents
FAX NO. 571-273-8300
PHONE NO.

FROM: Katherine L. Neville
PAGES (INCLUDING THIS PAGE): 11
PLEASE CONFIRM RECEIPT: Yes
MESSAGE:

EXTENSION: 829
CLIENT NO: 28967
MATTER NO: 37564B
COUNTRY CODE: US

Please contact Mary Vlasak at (312) 474-6829 if you do not receive all of the pages in good condition.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

RECEIVED
CENTRAL FAX CENTER

APR 27 2006

Docket No.: 28967/37564B
(PATENT)

I hereby certify that this correspondence is being facsimile transmitted to telephone no. (571) 273-9300, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 27, 2006

Signature: 
Katherine L. Neville

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of: Alitalo *et al*

Application No.: 10/669,176

Group Art Unit: 1647

Filed: September 23, 2003

Examiner: C. Borgeest, Ph.D.

For: VEGF-C or VEGF-D Materials and Methods for
Treatment of Neuropathologies

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is a response to a Restriction Requirement, mailed March 27, 2006, in the above-referenced application.

No fees are believed due in connection with this paper. However, if fees are deemed necessary, the Commissioner is hereby authorized to charge such fees to Marshall, Gerstein & Borun LLP deposit account number 13-2855.

Amendments to the specification: none.

Amendments to the claims: there are no amendments to the claims. A complete listing of claims begins on page 2.

Remarks begin on page 7 of this paper.